🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 98 of 116

  1. Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumors

    phase 1 small molecule active

    1 trial

  2. Invivo CAR-T

    Chongqing Precision Biotech Co., Ltd

    B-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  3. Iopofosine I 131

    Cellectar Biosciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  4. Ipatasertib

    Hoffmann-La Roche

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  5. Ipilimumab

    VACCINEX, INC.

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

    phase 1 mab active

    1 trial

  6. Ipilimumab

    Regeneron UK Limited

    Stage III Prostate Cancer

    phase 1 mab terminated

    1 trial

  7. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric cancer

    phase 1 small molecule active

    1 trial

  8. Irinotecan liposome II combination therapy regimen

    Chongqing Claruvis Pharmaceutical Co.,

    Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 small molecule active

    1 trial

  9. Itraconazole

    United Therapeutics Europe Ltd

    Non-small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  10. Ivosidenib

    Agios Netherlands B.V.

    IDH1 Mutation Myeloid Neoplasms

    phase 1 small molecule completed

    1 trial

  11. Ixazomib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  12. Ixazomib

    Takeda

    Precursor Cell Lymphoblastic Leukemia-lymphoma

    phase 1 small molecule terminated

    1 trial

  13. JANX007

    Janux Therapeutics

    Prostate Cancer

    phase 1 mab active

    1 trial

  14. JANX008

    Janux Therapeutics

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  15. JANX014

    Janux Therapeutics

    Prostate Cancer

    phase 1 mab active

    1 trial

  16. JNJ-56021927

    Janssen Cilag International NV

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule completed

    1 trial

  17. JR8603

    JiaRay Group

    Solid Tumors

    phase 1 small molecule active

    1 trial

  18. JSB462

    Novartis Pharmaceuticals

    Metastatic Prostate Cancer (mCRPC)

    phase 1 small molecule active

    1 trial

  19. JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

    Shanghai University of Traditional Chinese Medicine

    Diffuse Large B Cell Lymphoma

    phase 1 mab completed

    1 trial

  20. JZP341

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  21. JZP815

    Jazz Pharmaceuticals Ireland Limited

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  22. JZP898

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  23. Jakavi 10 mg tablets, CELECOXIB , Navitoclax, Navitoclax, Jakavi 10 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis, Myeloproliferative Neoplasms

    phase 1 small molecule active

    1 trial

  24. Jiu-wei-zhen-xiao Granule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  25. KCP-330

    Karyopharm Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial

  26. KFA115

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  27. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  28. KK-LC-1 TCR-T cells

    Iovance Biotherapeutics B.V.

    Gastric Cancer

    phase 1 mab active

    1 trial

  29. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura Oncology

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial

  30. KO-947

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  31. KPT-330

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  32. KPT-330

    Karyopharm Therapeutics Inc

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  33. KPT-330

    Karyopharm Therapeutics Inc

    Relapsed Acute Lymphoblastic Leukemia (ALL)

    phase 1 small molecule active

    1 trial

  34. KPT-9274

    Karyopharm Therapeutics Inc

    Solid Tumors

    phase 1 small molecule terminated

    1 trial

  35. KPT-9274

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  36. KRAS Vaccine with Poly-ICLC adjuvant

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  37. KSH01 injection

    TScan Therapeutics

    Solid Tumor

    phase 1 small molecule active

    1 trial

  38. KSV01 Injection

    TScan Therapeutics

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  39. KT-333

    Kymera Therapeutics

    Non Hodgkin Lymphoma (NHL)

    phase 1 small molecule completed

    1 trial

  40. KT-413

    Kymera Therapeutics

    Non Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  41. KXV01 TCR Lentinvivo Injection

    TScan Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    2 trials

  42. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  43. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Cancer

    phase 1 small molecule active

    1 trial

  44. LB-100 for Injection

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Tumors

    phase 1 small molecule completed

    1 trial

  45. LB1901

    Nanjing Legend Biotech Co.

    T-Cell Lymphoma

    phase 1 mab active

    1 trial

  46. LB1908

    Nanjing Legend Biotech Co.

    Gastric Cancer

    phase 1 mab active

    1 trial

  47. LB2102

    Nanjing Legend Biotech Co.

    Small Cell Lung Cancer Extensive Stage

    phase 1 mab active

    1 trial

  48. LCAR-AIO Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphocytic Leukemia

    phase 1 mab terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.